Why the study?
Is the traditional classification of Type I (irreversible) and Type II (reversible) cardiomyopathies still valid for anthracyclines and trastuzumab?
Is the traditional classification of Type I (irreversible) and Type II (reversible) cardiomyopathies still valid for anthracyclines and trastuzumab?
The traditional paradigm that anthracycline cardiotoxicity is irreversible and trastuzumab cardiotoxicity is reversible is challenged, prompting a call for a new classification system.
No takes yet. Share an insight, caveat, or question.
Bibliometric trends highlight expanding ICI cardiotoxicity research; leaves open need for prospective trials to guide surveillance and management.
Riccio et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: